Cost vs Efficacy · 2 points
| Regimen | Biomarker | Cost/cycle ↓ | Cycle | PFS ↕ | OS ↕ | Est. cycles | Course cost ↕ | Evidence |
|---|---|---|---|---|---|---|---|---|
MVEC Variant #01 | — | R 6 256 | 28d | 49.7 mo | — | 3 | R 18 767 PFS proxy | 1 |
PGC Variant #01 | — | R 4 667 | 21d | — | ~15.8 mo | ~4 | ~R 18 668 PFS proxy · indirect | 1 |
Cisplatin and Gemcitabine (GC) Variant #01 | — | R 3 933 | 21d | — | — | 6 | R 23 595 PFS proxy | 1 |
MCV Variant #01 | — | R 3 697 | 28d | — | ~44.0 mo | ~3 | ~R 11 090 PFS proxy · indirect | 1 |
Cisplatin and Methotrexate Variant #01 | — | R 661 | 21d | 43.4 mo | — | 3 | R 1 983 PFS proxy | 1 |
Nivolumab monotherapy Variant #01 Partial | — | — | 14d | — | 72.3 mo | 2 | — | 2 |
6 of 6 regimens shown